https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35727 Wed 14 Jun 2023 12:38:16 AEST ]]> A six-epithelial-mesenchymal transition gene signature may predict metastasis of triple-negative breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38374 Wed 01 Sep 2021 14:04:39 AEST ]]> Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16286 Sat 24 Mar 2018 07:59:27 AEDT ]]> Utilisation of MR spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25640 Sat 24 Mar 2018 07:28:09 AEDT ]]> The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32036 Fri 01 Apr 2022 09:24:05 AEDT ]]>